CYTEIR THERAPEUTICS INC (CYT)

US23284P1030 - Common Stock

3.02  -0.07 (-2.27%)

After market: 3.1 +0.08 (+2.65%)

News Image
9 months ago - Bloomberg

Biotech’s Drug Flop Turns Into Boon for Investors on Cash Return

A little-known biotech company, Cyteir Therapeutics Inc., is about to notch its best day ever — on the back of plans to dissolve the company.

News Image
a year ago - Seeking Alpha

Cyteir Therapeutics downgraded to neutral at BofA on pipeline prioritization (NASDAQ:CYT)

BofA Securities has downgraded Cyteir Therapeutics (CYT) to neutral from buy citing the company's recent decision on a pipeline prioritization to focus on combination therapies.

News Image
a year ago - Seeking Alpha

Cyteir Therapeutics (NASDAQ:CYT) to prioritize development of CYT-0851

Cyteir Therapeutics (CYT) will prioritize clinical development of CYT-0851 and reduce its workforce as part of the prioritization. Read more here.